Truist Securities raises Alkermes stock price target to $55 on positive trial data
PositiveFinancial Markets

- Truist Securities has increased Alkermes' stock price target to $55, driven by encouraging results from recent clinical trials. This adjustment highlights the firm's positive sentiment towards Alkermes' potential growth and market performance.
- The raised price target is significant for Alkermes as it may enhance investor confidence and attract more interest in the stock, potentially leading to increased trading volume and market capitalization.
- While there are no directly related articles, the emphasis on trial data suggests a broader trend in the biotech sector where positive clinical outcomes can substantially influence stock valuations.
— via World Pulse Now AI Editorial System